TomoTherapy (NASD: TOMO) completed an initial public offering in 2007 and was later acquired by Accuray (NASD: ARAY). The company provides a revolutionary, radiation treatment system that delivers conformal radiation therapy to cancer patients while limiting damage to surrounding healthy tissues.